Top Stroke Experts Join AI Development
"To Save More Lives"
From the left, JLK Ryu Wiseon, Chief Medical Officer, Sun Woojun, Director, Ko Eunjeong, Director. JLK
In order to safeguard the "golden hour" in stroke treatment, Korea's top stroke specialists have stepped beyond hospital walls to lead the development of new technologies. Three specialists from Seoul National University College of Medicine, each renowned in their respective fields of neurology, neurosurgery, and radiology, have joined the medical artificial intelligence (AI) company JLK. They are spearheading the development of an "all-in-one stroke AI solution," drawing significant attention from the industry. Rather than simply serving as technical advisors, they are actively involved at the core of development, infusing their extensive clinical experience into the AI itself.
At the heart of JLK's stroke AI solution development are Ryu Wiseon, Chief Medical Officer (CMO); Sun Woojun, Chief Medical Sub-Officer; and Ko Eunjeong, Chief Medical Sub-Officer. All three are alumni of Seoul National University College of Medicine and are recognized as leading experts in their fields, having published around 200 academic papers collectively.
Within JLK, they have drawn attention by publishing numerous international journal articles on brain disease research, including clinical studies on brain CT perfusion imaging analysis (Neuroradiology), deep learning-based automatic detection of large vessel occlusion (JNIS), and deep learning-based automatic segmentation of MRI brain infarction (Nature Scientific Reports).
Ryu Wiseon, Chief Medical Officer, is a distinguished scholar in the field of stroke, having graduated from Seoul National University College of Medicine and served as a professor of neurology at Dongguk University College of Medicine and director of the Korean Brain MR Imaging Data Center. He has published approximately 140 SCI-level papers and enjoys international recognition. Since joining JLK in 2022, he has emphasized, "AI must ultimately contribute to saving patients' lives and improving their quality of life," adding, "We are developing AI that acts as a companion to help capture subtle signals that medical staff might miss, supporting optimal treatment decisions."
Sun Woojun, Chief Medical Sub-Officer, is a specialist in neuro-head and neck radiology and also serves as a professor in the Department of Radiology at Seoul National University Bundang Hospital. Having conducted brain disease diagnosis research using AI for many years, he has published about 60 SCI-level papers and is considered one of the foremost authorities in this field. He highly values the potential of JLK's solution and is directly involved in advancing the AI solution from a radiology expert's perspective.
Ko Eunjeong, Chief Medical Sub-Officer and a veteran in the field of cerebral hemorrhage, is an elite medical professional who previously served as a professor in the Department of Neurosurgery and the Inpatient Medical Center at Seoul National University Hospital. She has accumulated extensive clinical experience in both adult and pediatric cerebral hemorrhage. Having joined JLK earlier this year, she stated, "For cerebral hemorrhage patients, even a single minute during the golden hour can determine life or death," adding, "Our goal is to help medical professionals establish the optimal treatment plan in the shortest time possible through AI."
JLK's stroke AI solution, developed through the collaboration of experts in the three core areas of cerebral infarction (neurology), cerebral hemorrhage (neurosurgery), and brain imaging interpretation (radiology), features a robust system that comprehensively covers the entire process from diagnosis to treatment. This approach directly reflects the reality that stroke treatment requires close cooperation among multiple specialties, now embodied in the AI's development.
Notably, the specialists' extensive clinical experience is expected to not only enhance the AI's accuracy but also serve as a key driver in maximizing its practical usability in real-world medical settings. By meticulously filtering out various variables and minor data errors that may arise on-site, they are implementing a user-centered solution optimized for the diagnostic workflow of medical professionals.
Additionally, the synergy is heightened by the collaboration of AI developers with master's and doctoral degrees and experts in mathematics and engineering from prestigious overseas universities. The process is designed so that specialists provide clinical direction, while the development team implements it with technical perfection, achieving both high accuracy and rapid processing speed. These two factors are especially crucial for protecting the golden hour for stroke patients, where every second counts.
The company is confident that its medical AI solution will become a "real-world" AI trusted by doctors and capable of saving patients' lives in actual clinical settings. It also expects that JLK's innovations, born from the hands of top medical experts, will offer new hope to countless stroke patients.
Kim Dongmin, CEO of JLK, stated, "To develop products optimized for the medical field, the best specialists and developers have come together to focus intensely on technological advancement and internal testing," adding, "We will continue to grow as a company that creates technologies capable of saving more lives in real medical settings."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
